A Study on the Safety and Efficacy of Apixaban for Thromboembolism Prevention versus No Systemic Anticoagulant Prophylaxis during Induction Chemotherapy in Children with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoma (T or B cell) Treated with Pegylated (PEG) L-asparaginase

About this Study

This study is looking at the safety and efficacy of giving an anticoagulant, apixaban, as prophylactic treatment to prevent the formation of clots/thrombus in patients with acute lymphoblastic leukemia and lymphoma.

Sponsor Protocol ID:ACCL1333/CV185-155
IRB Number:2015-0076
Actively Enrolling
Interventional
Phase 3
May 28, 2019
Eligibility Criteria
1 year old
18 years old
Both Male and Female
Yes
Yes
No

Inclusion Criteria
  • Able to tolerate oral medication or have it administered via an NGT or GT tube. 
  • Males and females, ages 1 year (365 days) to
  • Females of reproductive potential (FRP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) at screening. 
  • Women must not be breastfeeding. 

Exclusion Criteria
  • Prior history of documented DVT or PE in the past 3 months. 
  • Known inherited bleeding disorder or coagulopathy with increased bleeding risk. 
  • Major surgery (excluding CVAD replacement and bone marrow aspiration and non-open biopsy) within the last 7 days prior to enrollment that may be associated with an increase in the risk of bleeding. Open biopsy is considered a major surgery. 
  • Uncontrolled severe hypertension at enrollment.  
  • Extreme hyperleukocytosis. 
  • History of any significant drug allergy. 
  • Positive pregnancy test. 
  • Unable to take oral or enteric medication.  
  • Failure to provide written informed consent.  
  • Any investigational drug being administered during the study.

Categories Click category to view its trials.
Cancer
Pediatrics
Participating Locations
Children’s of Mississippi Hospital - Blair E. Batson Tower
Children's of Mississippi Center for Cancer and Blood Disorders
Contact Information
Contact Name: Theresa Hutson
Phone Number: 601-815-8702
Email: tlhickey@umc.edu
Principal Investigator:Takeki Suzuki
How to participate in our Clinical Trials